Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (364)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Pembrolizumab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Pembrolizumab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Nivolumab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Nivolumab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Denosumab |
RANKL Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Denosumab
Therapeutic Category
Bone-Modifying Agent
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
RANKL Inhibitor |
||||
Lutetium-177 Vipivotide Tetraxetan |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Lutetium-177 Vipivotide Tetraxetan
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Lutetium-177 Dotatate |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Lutetium-177 Dotatate
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Amivantamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Amivantamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Teclistamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Teclistamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Talquetamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Talquetamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Alpelisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Alpelisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Nab-Paclitaxel (Albumin-bound) |
Antimicrotubule Agent | Both (Solid & Hematologic) | ||
|
Molecule
Nab-Paclitaxel (Albumin-bound)
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Antimicrotubule Agent |
||||
Elranatamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Elranatamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Aclarubicin |
Anthracycline / Anthracenedione | Both (Solid & Hematologic) | ||
|
Molecule
Aclarubicin
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anthracycline / Anthracenedione |
||||
PembrolizumabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
NivolumabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
DenosumabBone-Modifying Agent |
|
|
Therapeutic Category
Bone-Modifying Agent
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
RANKL Inhibitor |
|
Lutetium-177 Vipivotide TetraxetanRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
Lutetium-177 DotatateRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
AmivantamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
TeclistamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
TalquetamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
AlpelisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
Nab-Paclitaxel (Albumin-bound)Cytotoxic Chemotherapy |
|
|
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Antimicrotubule Agent |
|
ElranatamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
AclarubicinCytotoxic Chemotherapy |
|
|
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anthracycline / Anthracenedione |
|